In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on AbSci (ABSI – Research Report), with a price ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 20.49% ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report), retaining the price target of $7.00. Swayampakula Ramakanth’s rating is based on several ...

Good day, and thank you for standing by. Welcome to the Absci Q3 2024 business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

Absci Corp (ABSI) showcases promising collaborations and a robust pipeline amid rising R&D expenses and revenue challenges.

and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended ...

Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...

Shares of Absci Co. (NASDAQ:ABSI – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have ...